CONMED (CNMD) Expected to Announce Earnings on Wednesday

CONMED (NYSE:CNMD) will likely be releasing its Q1 2025 earnings data after the market closes on Wednesday, April 30th. Analysts expect CONMED to post earnings of $0.81 per share and revenue of $313.38 million for the quarter. CONMED has set its FY 2025 guidance at 4.250-4.400 EPS.

CONMED (NYSE:CNMD) last released its quarterly earnings data on Wednesday, February 5th. The company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.20 by $0.14. CONMED had a net margin of 10.13% and a return on equity of 14.31%. On average, analysts expect CONMED to post $4 EPS for the current fiscal year and $5 EPS for the next fiscal year.

CONMED Stock Performance

CNMD opened at $50.94 on Tuesday. The company has a current ratio of 2.30, a quick ratio of 1.06 and a debt-to-equity ratio of 0.94. The company’s fifty day moving average price is $56.75 and its two-hundred day moving average price is $65.09. CONMED has a 1-year low of $46.00 and a 1-year high of $78.58. The company has a market cap of $1.58 billion, a price-to-earnings ratio of 12.01, a PEG ratio of 1.83 and a beta of 1.28.

CONMED Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, April 4th. Stockholders of record on Friday, March 14th were issued a $0.20 dividend. The ex-dividend date of this dividend was Friday, March 14th. This represents a $0.80 annualized dividend and a dividend yield of 1.57%. CONMED’s dividend payout ratio is currently 18.87%.

Analyst Ratings Changes

Several brokerages have recently commented on CNMD. Wells Fargo & Company lowered their target price on shares of CONMED from $74.00 to $70.00 and set an “equal weight” rating for the company in a report on Thursday, February 6th. JPMorgan Chase & Co. downgraded shares of CONMED from an “overweight” rating to a “neutral” rating and lowered their target price for the company from $85.00 to $70.00 in a report on Thursday, February 6th. Needham & Company LLC lowered their target price on shares of CONMED from $97.00 to $91.00 and set a “buy” rating for the company in a report on Thursday, February 6th. Finally, Stifel Nicolaus downgraded shares of CONMED from a “buy” rating to a “hold” rating and lowered their target price for the company from $75.00 to $55.00 in a report on Monday. Four research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $73.20.

CONMED Company Profile

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.